Abstract
ABSTRACT In untreated subjects insulin induced hypoglycaemia was followed by a marked increase in urinary adrenaline excretion without any significant change in noradrenaline, thus confirming previous observations. This stimulating effect of hypoglycaemia on adrenaline production could be markedly inhibited by treatment with the antihypertensive agent Catapresan® (2-(2,6-dichlorphenylamine)-2-imidazoline hydrochloride). The basal urinary noradrenaline excretion was markedly suppressed under medication with Catapresan® and again there was no significant change in connection with hypoglycaemia. Infusion studies demonstrated that Catapresan® did not influence the urinary recovery of adrenaline and noradrenaline. Thus, the diminished adrenaline excretion following Catapresan® represented a reduced secretion of the hormone. This inhibitory effect of Catapresan® might be due to an action of the compound on central nervous structures.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
